Risk of infection following CAR T-cell therapy for diffuse large B cell lymphoma

Infection is common in patients treated with CD19-directed chimeric antigen receptor T-cell therapy, but it is not associated with higher mortality
Infection is common in patients treated with CD19-directed chimeric antigen receptor T-cell therapy, but it is not associated with higher mortality